<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<html xmlns:n1="urn:hl7-org:v3" xmlns:in="urn:lantana-com:inline-variable-data" xmlns:sdtc="urn:hl7-org:sdtc"><head>
<meta charset="utf-8"><!-- Do NOT edit this HTML directly: it was generated via an XSLT transformation from a CDA Release 2 XML document. --><title>Progress note - [REDACTED]</title><style type="text/css">
body {
  color: #003366;
  background-color: #FFFFFF;
  font-family: Verdana, Tahoma, sans-serif;
  font-size: 14px;
}

a {
  color: #003366;
  background-color: #FFFFFF;
}

h1 {
  font-size: 20px;
  font-weight: bold;
}

h2 {
  font-size: 18px;
  font-weight: bold;
}

h3 {
  font-size: 14px;
  font-weight: bold;
}

h4 {
  font-size: 14px;
  font-weight: bold;
}


table {
  width: 100%;
}

th {
  background-color: #ffd700;
}

td {
  padding: 0.1cm 0.2cm;
  vertical-align: top;
  background-color: #ffffcc;
}

.h1center {
  font-size: 20px;
  font-weight: bold;
  text-align: center;
  width: 80%;
}

.header_table{
  border: 1pt inset #00008b;
}

.td_label{
  font-weight: bold;
  color: white;
}

.content_span{
 font-family: Verdana, Tahoma, sans-serif;
 display: inline;
 white-space: pre-line;
}

.td_header_role_name{
  width: 20%;
  background-color: #3399ff;
}

.td_header_role_value{
  width: 80%;
  background-color: #ccccff;
}

.Bold{
  font-weight: bold;
}

.Italics{
  font-style: italic;
}

.Underline{
  text-decoration:underline;
}

.internal_format
{
	list-style: none;
	list-style-position:outside;
	margin:0;
	padding:0;
	border:0;
	border-collapse: collapse;
}
          </style></head><body>
<h2><a name="toc">Table of Contents</a></h2><ul><li><a href="#id1">Allergies</a></li><li><a href="#id2">REASON FOR VISIT</a></li><li><a href="#id3">Medications</a></li><li><a href="#id4">Vital Signs</a></li><li><a href="#id5">Encounters</a></li><li><a href="#id6">Assessments</a></li><li><a href="#id7">Plan Of Treatment</a></li><li><a href="#id8">Progress Notes</a></li><li><a href="#id9">History and Physical Notes</a></li></ul><hr align="left" color="teal" size="2"/><h3><a name="id1" href="#toc">Allergies</a></h3><div><span class="content_span">No Known Allergies</span></div><h3><a name="id2" href="#toc">REASON FOR VISIT</a></h3><div>4wk follow up w/EKG (BIO)</div><h3><a name="id3" href="#toc">Medications</a></h3><div><table width="100%" border="1"><thead><tr><th>Medication</th><th>SIG (Take, Route, Frequency, Duration)</th><th>Notes</th><th>Start Date</th><th>End Date</th><th>Status</th></tr></thead><tbody><tr><td ID="medication1">Levothyroxine Sodium 75 MCG</td><td ID="instruction1">1 capsule on an empty stomach in the morning Orally Once a day</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication2">Vitamin D3</td><td ID="instruction2"/><td ID="medication2notes">1000IU</td><td/><td/><td>Active</td></tr><tr><td ID="medication3">ALPRAZolam 0.25 MG</td><td ID="instruction3"><p>1 tablet Orally Twice a day</p><p>As needed</p></td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication4">Latanoprost 0.005 %</td><td ID="instruction4">1 drop into affected eye in the evening Ophthalmic Once a day</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication5">Eliquis 2.5 mg</td><td ID="instruction5">1 tablet Orally twice a day for 90 days</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication6">dilTIAZem HCl ER 120 MG</td><td ID="instruction6">1 capsule Orally Twice a day</td><td/><td/><td/><td>Active</td></tr></tbody></table></div><h3><a name="id4" href="#toc">Vital Signs</a></h3><div><table width="100%" border="1"><tbody><tr><th ID="vital1">Blood pressure systolic</th><td>138 mm Hg</td><td>[REDACTED]</td></tr><tr><th ID="vital2">Blood pressure diastolic</th><td>84 mm Hg</td><td>[REDACTED]</td></tr><tr><th ID="vital3">Heart Rate</th><td>72 /min</td><td>[REDACTED]</td></tr><tr><th ID="vital4">Height</th><td>59 in</td><td>[REDACTED]</td></tr><tr><th ID="vital5">Weight</th><td>104 lbs</td><td>[REDACTED]</td></tr><tr><th ID="vital6">BMI</th><td>21 kg/m2</td><td>[REDACTED]</td></tr><tr><th ID="vital7">Oximetry</th><td>98 %</td><td>[REDACTED]</td></tr></tbody></table></div><h3><a name="id5" href="#toc">Encounters</a></h3><div><table width="100%" border="1"><thead><tr><th>Encounter</th><th>Location</th><th>Date</th><th>Provider</th><th>Diagnosis</th></tr></thead><tbody><tr><td>South Heart Clinic - [REDACTED]</td><td>[REDACTED][REDACTED][REDACTED]</td><td>[REDACTED]</td><td>[REDACTED]</td><td>Persistent atrial fibrillation I48.19</td></tr></tbody></table></div><h3><a name="id6" href="#toc">Assessments</a></h3><div><table width="100%" border="1"><thead><tr><th>Encounter Date</th><th>Diagnosis (ICD Code)</th><th>Assessment Notes</th><th>Treatment Notes</th><th>Treatment Clinical Notes</th><th>Section Notes</th></tr></thead><tbody><tr><td ID="ref1">[REDACTED]</td><td>Persistent atrial fibrillation (ICD-10 - I48.19)</td><td/><td><p>1.  She has been in persistent atrial fibrillation since [REDACTED] and underwent successful cardioversion in [REDACTED].  She reverted back to atrial fibrillation [REDACTED].  She does not appear to be symptomatic for the atrial fibrillation at this point.  She reports fatigue but admits that the fatigue occurs after she has been active. </p><p>2.  We discussed a gentle load of amiodarone followed by cardioversion versus continuing a rate control strategy.  At this point she wishes to continue with the rate control strategy.3.  She was advised to remain on Eliquis 2.5 mg twice daily for stroke prevention in the setting of atrial fibrillation.4.  Will schedule follow-up visit [REDACTED] or sooner as needed. -- NG</p></td><td/><td/></tr></tbody></table></div><h3><a name="id7" href="#toc">Plan Of Treatment</a></h3><div><span class="content_span">Treatment Notes</span><table width="100%" border="1"><thead><tr><th>Assessment</th><th>Notes</th></tr></thead><tbody><tr><td ID="instructionpot1">Persistent atrial fibrillation</td><td><p>1.  She has been in persistent atrial fibrillation since [REDACTED] and underwent successful cardioversion in [REDACTED].  She reverted back to atrial fibrillation [REDACTED].  She does not appear to be symptomatic for the atrial fibrillation at this point.  She reports fatigue but admits that the fatigue occurs after she has been active. </p><p>2.  We discussed a gentle load of amiodarone followed by cardioversion versus continuing a rate control strategy.  At this point she wishes to continue with the rate control strategy.3.  She was advised to remain on Eliquis 2.5 mg twice daily for stroke prevention in the setting of atrial fibrillation.4.  Will schedule follow-up visit [REDACTED] or sooner as needed. -- NG</p></td></tr></tbody></table><span class="content_span">Next Appt</span><table width="100%" border="1"><thead><tr><th>Details</th></tr></thead><tbody><tr><td ID="futureAppt1">Provider Name:[REDACTED], [REDACTED] 11:00:00 AM, [REDACTED][REDACTED][REDACTED], [REDACTED]</td></tr><tr><td ID="futureAppt2">Provider Name:[REDACTED], [REDACTED] 03:00:00 PM, [REDACTED][REDACTED]-8200, [REDACTED]</td></tr></tbody></table></div><h3><a name="id8" href="#toc">Progress Notes</a></h3><div><ul><li><table width="99%" border="0" cellspacing="0" cellpadding="0"><thead><tr><td><content>[REDACTED] <span class="bold">DOB:</span> [REDACTED] ([REDACTED] F) <span class="bold">Acc No.</span> 110091 <span class="bold">DOS:</span> [REDACTED]</content></td></tr></thead><tbody><tr><td><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td align="right" colspan="2"><span class="bold">Progress Notes</span></td></tr><tr><td align="left"><span class="bold">Patient: </span>[REDACTED]<br/><span class="bold">Account Number: </span>110091</td><td align="right"><span class="bold">Provider: </span>[REDACTED], MD</td></tr><tr><td align="left"/></tr><tr><td align="left"><span class="bold">DOB: </span>[REDACTED]<span class="bold">   Age: </span>92 Y<span class="bold">   Sex: </span>Female</td><td align="right"><span class="bold">Date: </span>[REDACTED]</td></tr><tr><td><span class="bold">Phone: </span>[REDACTED]</td></tr><tr><td colspan="2"><span class="bold">Address: </span>[REDACTED][REDACTED][REDACTED]</td></tr><tr><td colspan="2"><span class="bold">Pcp: </span>MD [REDACTED]</td></tr></tbody></table></li></ul><br/><content><span class="bold">Subjective:</span></content><br/><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Chief Complaints:</span></td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td>   1. 4wk follow up w/EKG (BIO). </td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">HPI: </span><br/>   <span class="Underline">**********</span>: <br/>       This is a [REDACTED] female here for follow up.  She has a history of complete heart block s/p dual chamber PPM implant 2012 with generator change out [REDACTED], and atrial arrhythmias including atrial tachycardia and now persistent atrial fibrillation.  She recently underwent successful cardioversion [REDACTED] and reverted back to atrial fibrillation [REDACTED], otherwise she has been in persistent atrial fibrillation since [REDACTED].  Her last visit we discussed initiation of amiodarone followed by cardioversion, however she did not want to undergo an additional procedure propafenone was withdrawn.<br/>She states that she is resting well and wakes up feeling energetic.  She performs a lot of household activities and when she begins to feel tired she takes a break.  She reports fatigue but states that this is generally after she has been occupied.  She underwent device interrogation [REDACTED] which revealed a presenting rhythm of atrial fibrillation otherwise normal device function.  She has an underlying rhythm of atrial fibrillation with ventricular pacing at 30 bpm.  She is RV pacing 100%.  Her EKG [REDACTED] demonstrates atrial fibrillation with ventricular pacing at 71 bpm.</td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Medical History:</span> Presentation the hospital with cardiogenic shock [REDACTED], Complete heart block [REDACTED], Status post dual-chamber pacemaker placement with Guidant device [REDACTED], Hypertension, ACE inhibitor induced cough, Intolerance to warfarin, tolerating Eliquis.</td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Family History:</span> <br/>htn.</td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Social History:</span> <br/>   Ms. Kokila denies smoking cigarettes or use of any tobacco products.<br/>Patient is married.</td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Medications:</span> Taking dilTIAZem HCl ER 120 MG Capsule Extended Release 12 Hour 1 capsule Orally Twice a day , Taking Latanoprost 0.005 % Solution 1 drop into affected eye in the evening Ophthalmic Once a day , Taking Eliquis 2.5 mg TABLET 1 tablet Orally twice a day , Taking Levothyroxine Sodium 75 MCG Tablet 1 capsule on an empty stomach in the morning Orally Once a day , Taking Vitamin D3      , Notes to Pharmacist: 1000IU, Taking ALPRAZolam 0.25 MG Tablet 1 tablet Orally Twice a day As needed, Discontinued Vitamin B 12 500 MCG Tablet 1 tablet Orally Once a day , Discontinued Biotin 5 MG Capsule 1 capsule Orally Once a day , Medication List reviewed and reconciled with the patient</td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Allergies:</span> N.K.D.A.</td></tr></tbody></table></li></ul><br/><content><span class="bold">Objective:</span></content><br/><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Vitals:</span> HR: 72 /min, BP: 138/84 mm Hg, Wt: 104 lbs, BMI: 21 Index, Ht: 59 in, Oxygen sat %: 98, Wt-kg: 47.17.<br/></td></tr></tbody></table></li></ul><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><content class="bold">Examination: <br/></content>   <span class="Underline">General Examination:</span><br/>      PHYSICAL EXAM: in no acute distress. <br/>      GENERAL:  normal landmarks. <br/>      HEENT normocephalic,  atraumatic. <br/>      LUNGS  Clear to auscultation bilaterally, no wheezes, rales, rhonchi. <br/>      HEART:  regular rate and rhythm, S1, S2 normal. <br/>      EXTREMITIES:  no edema, full range of motion.    <br/></td></tr><tr><td/></tr></tbody></table></li></ul><br/><content><span class="bold">Assessment:</span></content><br/><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Assessment: </span></td></tr><tr><td/></tr><tr><td>1. Persistent atrial fibrillation - I48.19 (Primary)   </td></tr></tbody></table></li></ul><br/><content><span class="bold">Plan:</span></content><br/><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">Treatment:</span></td></tr><tr><td><ul><li><table width="100%" cellpadding="0" cellspacing="0" border="1"><tbody><tr><td><span class="bold">1. Persistent atrial fibrillation</span> <br/>Notes: 1.  She has been in persistent atrial fibrillation since [REDACTED] and underwent successful cardioversion in [REDACTED].  She reverted back to atrial fibrillation [REDACTED].  She does not appear to be symptomatic for the atrial fibrillation at this point.  She reports fatigue but admits that the fatigue occurs after she has been active. <br/>2.  We discussed a gentle load of amiodarone followed by cardioversion versus continuing a rate control strategy.  At this point she wishes to continue with the rate control strategy.3.  She was advised to remain on Eliquis 2.5 mg twice daily for stroke prevention in the setting of atrial fibrillation.4.  Will schedule follow-up visit [REDACTED] or sooner as needed. -- NG  </td></tr><tr><td/></tr></tbody></table></li></ul></td></tr></tbody></table></li></ul><ul><li/></ul><br/><ul><li><table width="100%" border="0"><tbody><tr><td/></tr><tr><td valign="top"/></tr><tr><td/></tr><tr><td/></tr><tr><td valign="top">Electronic signature of [REDACTED] , MD  on [REDACTED] 01:08 PM CST</td></tr><tr><td valign="top">Sign off status: Pending</td></tr><tr><td/></tr></tbody></table></li></ul><span class="content_span"/></td></tr></tbody><tbody><tr><td><br/><ul><li><table width="100%" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td align="left"><span class="bold">Provider:</span> [REDACTED], MD</td><td align="right"><span class="bold">Date: </span>[REDACTED]</td></tr><tr><td/><td align="right"><span class="content_span">Generated for Printing/Faxing/eTransmitting on: [REDACTED] 01:08 PM CST</span></td></tr></tbody></table></li></ul></td></tr></tbody></table></li></ul></div><h3><a name="id9" href="#toc">History and Physical Notes</a></h3><div><ul><li><p>HPI (History of Present Illness)</p><table width="100%" border="1"><colgroup><col width="20%"/><col width="20%"/><col width="40%"/><col width="20%"/></colgroup><thead><tr><th>Category</th><th>Sub-Category</th><th>Detail</th><th>Notes</th><th>Category Notes</th></tr></thead><tbody><tr><td>**********</td><td/><td colspan="2"/><td><p>This is a [REDACTED] female here for follow up.  She has a history of complete heart block s/p dual chamber PPM implant 2012 with generator change out [REDACTED], and atrial arrhythmias including atrial tachycardia and now persistent atrial fibrillation.  She recently underwent successful cardioversion [REDACTED] and reverted back to atrial fibrillation [REDACTED], otherwise she has been in persistent atrial fibrillation since [REDACTED].  Her last visit we discussed initiation of amiodarone followed by cardioversion, however she did not want to undergo an additional procedure propafenone was withdrawn.</p><p>She states that she is resting well and wakes up feeling energetic.  She performs a lot of household activities and when she begins to feel tired she takes a break.  She reports fatigue but states that this is generally after she has been occupied.  She underwent device interrogation [REDACTED] which revealed a presenting rhythm of atrial fibrillation otherwise normal device function.  She has an underlying rhythm of atrial fibrillation with ventricular pacing at 30 bpm.  She is RV pacing 100%.  Her EKG [REDACTED] demonstrates atrial fibrillation with ventricular pacing at 71 bpm.</p></td></tr></tbody></table><br/><p>Examination</p><table width="100%" border="1"><colgroup><col width="20%"/><col width="20%"/><col width="40%"/><col width="20%"/></colgroup><thead><tr><th>Category</th><th>Sub-Category</th><th>Detail</th><th>Notes</th><th>Category Notes</th></tr></thead><tbody><tr><td rowspan="6">General Examination</td><td>PHYSICAL EXAM:</td><td colspan="2">in no acute distress</td><td rowspan="6"/></tr><tr><td>HEENT</td><td colspan="2">normocephalic, atraumatic</td></tr><tr><td>HEART:</td><td colspan="2">regular rate and rhythm, S1, S2 normal</td></tr><tr><td>LUNGS</td><td colspan="2">Clear to auscultation bilaterally, no wheezes, rales, rhonchi</td></tr><tr><td>EXTREMITIES:</td><td colspan="2">no edema, full range of motion</td></tr><tr><td>GENERAL:</td><td colspan="2">normal landmarks</td></tr></tbody></table><br/></li></ul></div><br/><br/>
</body></html>